Current studies have demonstrated that intracellularly-localized EGFR is associated with poor prognosis, increased malignant potential, and decreased disease-free survival rates of patients with squamous cell and ovarian carcinomas [26, 56, 57]. The gene discussed is EGFR; the disease is ovarian squamous cell carcinoma.